Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An analysis of the liquidity metrics from March 2022 through March 2026 reveals a consistent downward trend in overall liquidity ratios, although all values remained significantly above standard industry benchmarks throughout the period. A notable acceleration in the decline occurred during the second quarter of 2024, followed by a period of relative stabilization and a modest recovery in late 2025 and early 2026.
- Current Ratio
- The current ratio began at 4.75 in March 2022, reaching a peak of 4.83 in December 2022. A gradual decline followed until March 2024 (3.50), at which point a sharp contraction occurred, dropping the ratio to 2.52 by June 2024. After fluctuating between 2.36 and 2.69 for several quarters, the ratio showed a recovery trend starting in December 2025, concluding at 3.02 in March 2026.
- Quick Ratio
- The quick ratio closely mirrored the trajectory of the current ratio, starting at 4.37 and peaking at 4.46 in December 2022. A significant reduction is observed between March 2024 (3.15) and June 2024 (2.10). The ratio reached its lowest point of 1.84 in September 2025 before ascending to 2.38 by the end of the analyzed period.
- Cash Ratio
- The cash ratio followed a nearly identical pattern, peaking at 3.93 in December 2022. Similar to the other metrics, a steep decline was recorded in the second quarter of 2024, moving from 2.68 to 1.63. The ratio bottomed at 1.40 in September 2025 and subsequently rose to 1.87 by March 2026.
The high degree of correlation and narrow variance between the current, quick, and cash ratios indicates that the company's current assets are predominantly composed of cash and cash equivalents, with very little weight attributed to inventories. Despite the overall decrease in these ratios over the four-year span, the liquidity position remained exceptionally strong, as all three ratios stayed well above the 1.0 threshold, indicating a sustained capacity to cover short-term liabilities.
Current Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
An analysis of the liquidity position from March 31, 2022, to March 31, 2026, reveals a general downward trend in the current ratio, characterized by a significant contraction in current assets during 2024 and a steady increase in short-term obligations.
- Current Assets Trend
- Current assets exhibited an initial growth phase, peaking at approximately 14.7 billion US$ in September 2023. This was followed by a sharp decline between March 31, 2024, and June 30, 2024, where assets fell from 13.29 billion US$ to 8.94 billion US$. Following this trough, a gradual recovery trend is observed, with assets climbing back to 11.73 billion US$ by December 31, 2025, and reaching 11.73 billion US$ by March 31, 2026.
- Current Liabilities Trend
- Current liabilities demonstrated a consistent upward trajectory for the majority of the period. Starting at 2.18 billion US$ in March 2022, obligations rose steadily to a peak of 4.48 billion US$ by June 30, 2025. While there was a notable reduction to 3.86 billion US$ in December 2025, the overall liability profile remains significantly higher than the baseline established in 2022.
- Current Ratio Interpretation
- The current ratio, reflecting the ability to cover short-term liabilities with short-term assets, began at a robust 4.75 in March 2022. A persistent decline is observed throughout 2023 and 2024, with a sharp drop to 2.52 by June 30, 2024. The ratio reached its lowest point of 2.36 on September 30, 2025. However, the final quarters of the period show a moderate recovery, with the ratio improving to 3.02 by March 31, 2026. Despite this recovery, the long-term trend indicates a reduction in the liquidity cushion compared to the 2022-2023 period.
Quick Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Marketable securities | |||||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity profile of the company exhibits a general downward trend in the quick ratio over the analyzed period, transitioning from a position of extreme liquidity to a more moderate, though still robust, financial standing. While the ratio remains well above the 1.0 threshold, indicating a consistent ability to cover short-term obligations with liquid assets, the margin of safety has narrowed significantly between March 2022 and March 2026.
- Quick Asset Trends
- Total quick assets demonstrated an initial growth phase, rising from 9.53 billion USD in March 2022 to a peak of 13.47 billion USD in September 2023. This was followed by a substantial contraction in the first half of 2024, with assets falling to a low of 7.45 billion USD by June 30, 2024. In the subsequent periods leading up to March 2026, quick assets showed a gradual recovery, ending at 9.24 billion USD.
- Current Liabilities Trajectory
- Current liabilities followed a generally upward trajectory, increasing from 2.18 billion USD in March 2022 to 3.88 billion USD by March 2026. This steady increase in short-term obligations contributed to the overall compression of the liquidity ratio, particularly as the growth in liabilities persisted even during periods of declining quick assets.
- Quick Ratio Interpretation
- The quick ratio began at a high of 4.37 in March 2022, reflecting an exceptionally high buffer of liquid assets. A period of steady decline followed, with the ratio dropping to 3.15 by March 2024. A sharp correction occurred in June 2024, where the ratio fell to 2.10. From June 2024 through March 2026, the ratio stabilized, fluctuating within a range of 1.84 to 2.38. This indicates a shift from a surplus-heavy liquidity strategy to a more streamlined balance sheet while maintaining sufficient coverage to meet immediate financial commitments.
Cash Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Marketable securities | |||||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity position of the entity exhibits a distinct transition from a period of high cash surplus to a more streamlined liquidity profile. Between March 2022 and March 2024, a consistently strong cash position was maintained, followed by a significant contraction in liquid assets during the second quarter of 2024. Despite this reduction, the cash ratio has remained above 1.0 throughout the entire period, indicating that current liabilities are always fully covered by cash assets.
- Peak Liquidity Phase (March 2022 – December 2023)
- During this interval, the cash ratio fluctuated between a low of 3.16 and a peak of 3.93. Total cash assets grew steadily from 8.24 billion USD in March 2022 to a peak of 11.93 billion USD in September 2023. This period was characterized by an aggressive accumulation of liquid reserves that far exceeded the growth rate of current liabilities, resulting in a highly conservative liquidity posture.
- Liquidity Contraction (March 2024 – June 2024)
- A sharp decline in the cash ratio is observed between March 31, 2024, and June 30, 2024, where the ratio dropped from 2.68 to 1.63. This was driven by a substantial reduction in total cash assets, which fell from 10.17 billion USD to 5.80 billion USD within a single quarter. This precipitous drop suggests a significant cash outflow, potentially related to strategic investments, acquisitions, or shareholder returns.
- Stabilization and Recovery Phase (June 2024 – March 2026)
- Following the sharp decline in mid-2024, the cash ratio reached a trough of 1.40 in September 2025. Subsequently, a recovery trend emerged, with the ratio climbing to 1.87 by March 31, 2026. This recovery is supported by a gradual increase in cash assets from 5.80 billion USD in June 2024 to 7.25 billion USD by the end of the observed period, alongside a stabilization of current liabilities.
Overall, while the cash ratio has decreased significantly from its historical highs, the current trend indicates a stabilization of liquidity. The shift from a ratio nearing 4.0 to one fluctuating between 1.4 and 1.9 represents a transition toward a less conservative but still healthy liquidity management strategy, ensuring all short-term obligations remain comfortably covered by available cash.